Skip to main content
SpringerLink
Log in

Radiation Therapy: Brachytherapy

  • Chapter
Interventional Urology

  • 1343 Accesses

Abstract

Prostate brachytherapy is an interventional procedure that is highly safe and effective for the treatment of localized prostate cancer. Brachytherapy offers equivalent to superior biochemical outcomes when compared to external beam radiation therapy and radical prostatectomy but offers an attractive toxicity prolife, improved quality of life, and preservation of sexual function when compared to these modalities. Modern prostate brachytherapy has benefitted significantly from the integration of advanced radiologic technologies, which have led to significant advances in the diagnosis and staging of prostate cancer, in the intraoperative imaging and placement of radioactive sources, and in the dosimetric assessment and toxicity management of patients undergoing prostate brachytherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189:S2–11.

    Article  PubMed  Google Scholar 

  3. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.

    Article  PubMed  Google Scholar 

  4. Andriole GL, Crawford ED, Grubb 3rd RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11:6–19.

    Article  PubMed  Google Scholar 

  6. Chen AB, D’Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24:5298–304.

    Article  PubMed  Google Scholar 

  7. Keyes M, Miller S, Moravan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009;73:1023–32.

    Article  PubMed  Google Scholar 

  8. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57–64.

    Article  PubMed  Google Scholar 

  9. Rifkin MD, Zerhouni EA, Gatsonis CA, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med. 1990;323:621–6.

    Article  CAS  PubMed  Google Scholar 

  10. Beerlage HP, Aarnink RG, Ruijter ET, et al. Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology of radical prostatectomy specimen. Prostate Cancer Prostatic Dis. 2001;4:56–62.

    Article  PubMed  Google Scholar 

  11. Hricak H, Dooms GC, McNeal JE, et al. MR imaging of the prostate gland: normal anatomy. AJR Am J Roentgenol. 1987;148:51–8.

    Article  CAS  PubMed  Google Scholar 

  12. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal – pelvic phased-array coils. Radiology. 1994;193:703–9.

    Article  CAS  PubMed  Google Scholar 

  13. Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology. 2008;246:168–76.

    Article  PubMed  Google Scholar 

  14. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2 – sparse versus dense cancers. Radiology. 2008;249:900–8.

    Article  PubMed  Google Scholar 

  15. Bonekamp D, Macura KJ. Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate. Top Magn Reson Imaging. 2008;19:273–84.

    Article  PubMed  Google Scholar 

  16. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol. 2007;63:335–50.

    Article  PubMed  Google Scholar 

  17. Jacobs MA, Ouwerkerk R, Petrowski K, Macura KJ. Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. Top Magn Reson Imaging. 2008;19:261–72.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol. 2007;63:351–60.

    Article  PubMed  Google Scholar 

  19. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59:962–77.

    Article  PubMed  Google Scholar 

  20. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–58.

    Article  PubMed  Google Scholar 

  21. Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol. 2007;42:842–7.

    Article  PubMed  Google Scholar 

  22. De Meerleer G, Villeirs G, Bral S, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol. 2005;75:325–33.

    Article  PubMed  Google Scholar 

  23. Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69:62–9.

    Article  PubMed  Google Scholar 

  24. Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010;58:57–64.

    Article  PubMed  Google Scholar 

  25. Roy JN, Wallner KE, Harrington PJ, Ling CC, Anderson LL. A CT-based evaluation method for permanent implants: application to prostate. Int J Radiat Oncol Biol Phys. 1993;26:163–9.

    Article  CAS  PubMed  Google Scholar 

  26. Salembier C, Lavagnini P, Nickers P, et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007;83:3–10.

    Article  PubMed  Google Scholar 

  27. Dubois DF, Prestidge BR, Hotchkiss LA, Prete JJ, Bice Jr WS. Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. Radiology. 1998;207:785–9.

    Article  CAS  PubMed  Google Scholar 

  28. Al-Qaisieh B. Pre- and post-implant dosimetry: an inter-comparison between UK prostate brachytherapy centres. Radiother Oncol. 2003;66:181–3.

    Article  PubMed  Google Scholar 

  29. Smith WL, Lewis C, Bauman G, et al. Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. Int J Radiat Oncol Biol Phys. 2007;67:1238–47.

    Article  PubMed  Google Scholar 

  30. Charyulu KK. Transperineal interstitial implantation of prostate cancer: a new method. Int J Radiat Oncol Biol Phys. 1980;6:1261–6.

    Article  CAS  PubMed  Google Scholar 

  31. Holm HH. The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol. 1997;13:431–7.

    Article  CAS  PubMed  Google Scholar 

  32. Buyyounouski MK, Davis BJ, Prestidge BR, et al. A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. Brachytherapy. 2012;11:299–305.

    Article  PubMed  Google Scholar 

  33. Orio 3rd PF, Tutar IB, Narayanan S, et al. Intraoperative ultrasound-fluoroscopy fusion can enhance prostate brachytherapy quality. Int J Radiat Oncol Biol Phys. 2007;69:302–7.

    Article  PubMed  Google Scholar 

  34. Prestidge BR, Prete JJ, Buchholz TA, et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys. 1998;40:461–5.

    Article  CAS  PubMed  Google Scholar 

  35. Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81–94.

    Article  PubMed  Google Scholar 

  36. Battermann JJ, van Es CA. The learning curve in prostate seed implantation. Cancer Radiother. 2000;4 Suppl 1:119s–22s.

    PubMed  Google Scholar 

  37. Older RA, Synder B, Krupski TL, Glembocki DJ, Gillenwater JY. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. J Urol. 2001;165:1590–2.

    Article  CAS  PubMed  Google Scholar 

  38. Tapen EM, Blasko JC, Grimm PD, et al. Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;42:1063–7.

    Article  CAS  PubMed  Google Scholar 

  39. Merrick GS, Butler WM, Dorsey AT, Lief JH, Benson ML. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys. 2000;46:215–20.

    Article  CAS  PubMed  Google Scholar 

  40. Eshleman JS, Davis BJ, Pisansky TM, et al. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys. 2004;59:419–25.

    Article  PubMed  Google Scholar 

  41. Al-Qaisieh B, Carey B, Ash D, Bottomley D. The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:397–9.

    Article  PubMed  Google Scholar 

  42. Fuller DB, Koziol JA, Feng AC. Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. Brachytherapy. 2004;3:10–9.

    Article  PubMed  Google Scholar 

  43. Reed DR, Wallner KE, Merrick GS, et al. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy. 2007;6:129–34.

    Article  PubMed  Google Scholar 

  44. Heysek RV, Gwede CK, Torres-Roca J, et al. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy. 2006;5:244–50.

    Article  PubMed  Google Scholar 

  45. Lin K, Lee SP, Cho JS, Reiter RE, DeMarco JJ, Solberg TD. Improvements in prostate brachytherapy dosimetry due to seed stranding. Brachytherapy. 2007;6:44–8.

    Article  PubMed  Google Scholar 

  46. Fagundes HM, Keys RJ, Wojcik MF, Radden MA, Bertelsman CG, Cavanagh WA. Transperineal TRUS-guided prostate brachytherapy using loose seeds versus RAPIDStrand: a dosimetric analysis. Brachytherapy. 2004;3:136–40.

    Article  PubMed  Google Scholar 

  47. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–8.

    Article  CAS  PubMed  Google Scholar 

  48. Papagikos MA, Deguzman AF, Rossi PJ, McCullough DL, Clark PE, Lee WR. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy. 2005;4:252–8.

    Article  PubMed  Google Scholar 

  49. Fogh S, Doyle L, Yu A, et al. A comparison of preplan transrectal ultrasound with preplan-CT in assessing volume and number of seeds needed for real-time ultrasound-based intra-operative planning in prostate (125)I seed implantation. Brachytherapy. 2010;9:335–40.

    Article  PubMed  Google Scholar 

  50. Crook JM, Potters L, Stock RG, Zelefsky MJ. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Brachytherapy. 2005;4:186–94.

    Article  PubMed  Google Scholar 

  51. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.

    Article  CAS  PubMed  Google Scholar 

  52. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33.

    Article  PubMed  Google Scholar 

  53. Colberg JW, Decker RH, Khan AM, McKeon A, Wilson LD, Peschel RE. Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005. Cancer J. 2007;13:229–32.

    Article  PubMed  Google Scholar 

  54. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.

    Article  PubMed  Google Scholar 

  55. Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79:1336–42.

    Article  PubMed  Google Scholar 

  56. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–6.

    Article  PubMed  Google Scholar 

  57. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol. 2000;57:263–7.

    Article  CAS  PubMed  Google Scholar 

  58. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40.

    Article  CAS  PubMed  Google Scholar 

  59. Sharkey J, Cantor A, Solc Z, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy. 2005;4:34–44.

    Article  PubMed  Google Scholar 

  60. Zelefsky MJ, Yamada Y, Cohen GN, et al. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications. Radiother Oncol. 2007;84:185–9.

    Article  PubMed  Google Scholar 

  61. Hinnen KA, Battermann JJ, van Roermund JG, et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;76:1433–8.

    Article  PubMed  Google Scholar 

  62. Henry AM, Al-Qaisieh B, Gould K, et al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of Leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys. 2010;76:50–6.

    Article  PubMed  Google Scholar 

  63. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187–92.

    CAS  PubMed  Google Scholar 

  64. Cosset JM, Flam T, Thiounn N, et al. Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital group on 809 patients. Int J Radiat Oncol Biol Phys. 2008;71:1042–8.

    Article  PubMed  Google Scholar 

  65. Morris WJ, Keyes M, Palma D, et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology. 2009;73:860–5. discussion 5-7.

    Article  CAS  PubMed  Google Scholar 

  66. Critz FA, Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol. 2004;172:2232–8.

    Article  PubMed  Google Scholar 

  67. Potters L, Freeman K. Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer. JAMA. 1999;281:1584; author reply 5–6.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Medicine, North Shore LIJ Health System, Lake Success, NY, USA

    Brett Cox MD

  2. Department of Radiation Medicine, North Shore LIJ Health System, Center for Advanced Medicine, Lake Success, NY, USA

    Lucille Lee MD & Louis Potters MD

Authors
  1. Brett Cox MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucille Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Louis Potters MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louis Potters MD .

Editor information

Editors and Affiliations

  1. Focal Therapy and Interventional Urologic Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

    Ardeshir R. Rastinehad

  2. Department of Radiology, Hofstra North Shore LIJ School of Medici Department of Radiology, New Hyde Park, New York, USA

    David N. Siegel

  3. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Peter A. Pinto

  4. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Bradford J. Wood

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Cox, B., Lee, L., Potters, L. (2016). Radiation Therapy: Brachytherapy. In: Rastinehad, A., Siegel, D., Pinto, P., Wood, B. (eds) Interventional Urology. Springer, Cham. https://doi.org/10.1007/978-3-319-23464-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23464-9_14

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23463-2

  • Online ISBN: 978-3-319-23464-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation